Parmax Pharma Ltd

Parmax Pharma Ltd

Parmax Pharma Ltd has announced the closure of the trading window for its designated persons from October 1, 2026, until 48 hours after the declaration of the financial results for the quarter and half year ending September 30, 2026.

Parmax Pharma Ltd

Parmax Pharma Ltd has informed the exchange about a major fire incident at its plant, which occurred on September 28, 2026, at 2:00 a.m. The fire was successfully controlled, and two employees were injured. The company is assessing the extent of damage and will keep the exchange informed of any further developments.

Parmax Pharma Ltd

Parmax Pharma Ltd has published a newspaper notice for its 32nd Annual General Meeting (AGM) scheduled on September 29, 2026, through Video Conferencing/Other Audio Visual Means.

Parmax Pharma Ltd

Parmax Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the acquisition of 22,80,444 shares and 17,16,574 warrants by Dhiren Chandulal Shah and Sunil Chinubhai Shah, and other persons acting in concert, from the company's promoter group.

Parmax Pharma Ltd

Parmax Pharma Ltd has allotted 31,37,586 equity shares and 21,45,145 convertible warrants on a preferential basis to non-promoter category investors at an issue price of ₹36.50 per share and ₹36.50 per warrant respectively.

Parmax Pharma Ltd

Parmax Pharma Ltd has informed the BSE about the reclassification of promoters under Regulation 31A of SEBI (LODR) Regulations, 2015. The company has received undertakings from the erstwhile promoters seeking reclassification confirming compliance with the conditions as specified under clauses (b) and (c)(ii)&(iii) of sub-regulation (3) of Regulation 31A of SEBI LODR Regulations.

Parmax Pharma Ltd

Parmax Pharma Ltd has submitted a copy of Post Offer Advertisement to BSE as per Regulation 18(12) of the Securities and Exchange Board of India (SAST) Regulations, 2011, in relation to the open offer for acquisition of up to 23,46,250 equity shares of the company.

Parmax Pharma Ltd

Parmax Pharma Ltd has received in-principle approval from BSE Limited under Regulation 28(1) of the SEBI LODR Regulations for the issuance of equity shares and warrants on a preferential basis.

Parmax Pharma Ltd

Parmax Pharma Ltd has announced the newspaper publication of the extract of financial results for the quarter ended June 30, 2026, as per Regulation 30 of the SEBI (LODR) Regulations, 2015. The company has also announced the notice of its 20th Annual General Meeting (AGM) to be held on September 8, 2026, through video conferencing.

Parmax Pharma Ltd

Parmax Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Alkesh Mahasukhlal Gopani & Others, indicating a potential change in shareholding.

Parmax Pharma Ltd

Parmax Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, stating that Dhiren Chandulal Shah and Sunil Chinubhai Shah have acquired 11,52,450 equity shares of the company on August 13, 2026, pursuant to a Share Purchase Agreement dated June 08, 2026. This acquisition has increased their shareholding in the company to 58.01%.

Parmax Pharma Ltd

Parmax Pharma Ltd announced the appointment of Mr. Dhiren Shah, Mr. Sunil Shah as Additional Directors and recommendation of Ms. Anjana Shah, Ashish Shah as Independent Directors. The company also released unaudited financial results for the quarter ended June 30, 2026.

Parmax Pharma Ltd

Parmax Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, reporting a net profit of Rs. 21,994.93 lakhs. The company's revenue from operations was Rs. 82,209.52 lakhs, and its expenses totaled Rs. 81,005.89 lakhs. The board of directors has also approved the appointment of four new directors, including Mr. Dhiren Chandulal Shah as the Chairman of the company.

Parmax Pharma Ltd

Parmax Pharma Ltd announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 21994.93 and a loss of Rs. 5843.31. The company also announced the appointment of new directors and the resignation of an existing director. The results were reviewed by the Audit Committee and approved by the Board of Directors.

Parmax Pharma Ltd

Parmax Pharma Ltd has received a disclosure under Regulation 18(6) of SEBI (SAST) Regulations, 2011, regarding the acquisition of 11,52,450 equity shares by Dhiren Chandulal Shah and Sunil Chinubhai Shah, and other persons, pursuant to a Share Purchase Agreement dated June 08, 2026.

Parmax Pharma Ltd

Parmax Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve quarterly financial results for the quarter ended June 30, 2026.

Parmax Pharma Ltd

Parmax Pharma Ltd has submitted a copy of newspaper publication of Offer Opening Pre-Offer Advertisement to the Public Shareholders of Parmax Pharma Ltd as part of the open offer for acquisition of up to 23,46,250 equity shares, representing 26% of the expanded voting share capital, by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with other persons acting in concert.

Parmax Pharma Ltd

Parmax Pharma Ltd has received a copy of the newspaper publication of the Committee of Independent Directors' (IDC) recommendations to public shareholders regarding an open offer for the acquisition of up to 23,46,250 equity shares, representing 26% of the company's expanded voting share capital, by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with other persons acting in concert.

Parmax Pharma Ltd

Parmax Pharma Ltd has received a letter of offer from Fedex Securities Pvt Ltd, the manager to the offer, for the acquisition of up to 23,46,250 equity shares, representing 26% of the expanded voting capital, by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with 10 persons acting in concert, at a price of ₹42.80 per equity share.

Parmax Pharma Ltd

Parmax Pharma Ltd has issued a corrigendum to its Extraordinary General Meeting (EGM) notice dated June 8, 2026, which was called for a preferential issue of equity shares and convertible warrants. The corrigendum corrects the proposed status of Ms. Sheetal Hiren Doshi in the warrant allottees table from 'Promoter*' to 'Promoter Group*'. Additionally, a hyperlink for the Practicing Company Secretary’s Certificate in the explanatory statement has been rectified. All other items of the EGM Notice remain unchanged, with the EGM scheduled for July 2, 2026.